# Allan Lawrie

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 120 papers | 4,302 citations | 38 h-index | 63 g-index |
| 164 ext. papers | 5,499 ext. citations | 8.9 avg, IF | 5.18 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 120 | Microbubble-enhanced ultrasound for vascular gene delivery. *Gene Therapy*, **2000**, 7, 2023-7 | 4 | 303 |
| 119 | ASPIRE registry: assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre. *European Respiratory Journal*, **2012**, 39, 945-55 | 13.6 | 260 |
| 118 | Comprehensive Rare Variant Analysis via Whole-Genome Sequencing to Determine the Molecular Pathology of Inherited Retinal Disease. *American Journal of Human Genetics*, **2017**, 100, 75-90 | 11 | 235 |
| 117 | Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. *Nature Communications*, **2018**, 9, 1416 | 17.4 | 182 |
| 116 | Ultrasound enhances reporter gene expression after transfection of vascular cells in vitro. *Circulation*, **1999**, 99, 2617-20 | 16.7 | 169 |
| 115 | Ultrasound gene therapy: on the road from concept to reality. *Echocardiography*, **2001**, 18, 339-47 | 1.5 | 139 |
| 114 | Interdependent serotonin transporter and receptor pathways regulate S100A4/Mts1, a gene associated with pulmonary vascular disease. *Circulation Research*, **2005**, 97, 227-35 | 15.7 | 135 |
| 113 | Reduced microRNA-150 is associated with poor survival in pulmonary arterial hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 187, 294-302 | 10.2 | 126 |
| 112 | Pulmonary hypertension in COPD: results from the ASPIRE registry. *European Respiratory Journal*, **2013**, 41, 1292-301 | 13.6 | 117 |
| 111 | Targeting Vascular Remodeling to Treat Pulmonary Arterial Hypertension. *Trends in Molecular Medicine*, **2017**, 23, 31-45 | 11.5 | 108 |
| 110 | Germline selection shapes human mitochondrial DNA diversity. *Science*, **2019**, 364, | 33.3 | 105 |
| 109 | TNF-related apoptosis-inducing ligand (TRAIL) regulates inflammatory neutrophil apoptosis and enhances resolution of inflammation. *Journal of Leukocyte Biology*, **2011**, 90, 855-65 | 6.5 | 103 |
| 108 | Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension. *Circulation*, **2017**, 135, 460-475 | 16.7 | 96 |
| 107 | MicroRNA-140-5p and SMURF1 regulate pulmonary arterial hypertension. *Journal of Clinical Investigation*, **2016**, 126, 2495-508 | 15.9 | 96 |
| 106 | Low-Dose FK506 (Tacrolimus) in End-Stage Pulmonary Arterial Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2015**, 192, 254-7 | 10.2 | 86 |
| 105 | Discovery of Distinct Immune Phenotypes Using Machine Learning in Pulmonary Arterial Hypertension. *Circulation Research*, **2019**, 124, 904-919 | 15.7 | 81 |
| 104 | Magnetic Resonance Imaging in the Prognostic Evaluation of Patients with Pulmonary Arterial Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 196, 228-239 | 10.2 | 79 |

| | | | |
|---|---|---|---|
| 103 | Phenotypic Characterization of Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension. *Circulation*, **2017**, 136, 2022-2033 | 16.7 | 75 |
| 102 | S100A4 and bone morphogenetic protein-2 codependently induce vascular smooth muscle cell migration via phospho-extracellular signal-regulated kinase and chloride intracellular channel 4. *Circulation Research*, **2009**, 105, 639-47, 13 p following 647 | 15.7 | 69 |
| 101 | Inhibition of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) reverses experimental pulmonary hypertension. *Journal of Experimental Medicine*, **2012**, 209, 1919-35 | 16.6 | 67 |
| 100 | Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension. *American Journal of Pathology*, **2008**, 172, 256-64 | 5.8 | 65 |
| 99 | Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study. *Lancet Respiratory Medicine,the*, **2017**, 5, 717-726 | 35.1 | 62 |
| 98 | Epigenetic Dysregulation of the Dynamin-Related Protein 1 Binding Partners MiD49 and MiD51 Increases Mitotic Mitochondrial Fission and Promotes Pulmonary Arterial Hypertension: Mechanistic and Therapeutic Implications. *Circulation*, **2018**, 138, 287-304 | 16.7 | 62 |
| 97 | Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. *Lancet Respiratory Medicine,the*, **2019**, 7, 227-238 | 35.1 | 55 |
| 96 | Osteoprotegerin in Cardiometabolic Disorders. *International Journal of Endocrinology*, **2015**, 2015, 564934 | 3.7 | 54 |
| 95 | Ultrasound-enhanced transgene expression in vascular cells is not dependent upon cavitation-induced free radicals. *Ultrasound in Medicine and Biology*, **2003**, 29, 1453-61 | 3.5 | 54 |
| 94 | Ultrasound-mediated delivery of TIMP-3 plasmid DNA into saphenous vein leads to increased lumen size in a porcine interposition graft model. *Gene Therapy*, **2005**, 12, 1154-7 | 4 | 48 |
| 93 | Paigen diet-fed apolipoprotein E knockout mice develop severe pulmonary hypertension in an interleukin-1-dependent manner. *American Journal of Pathology*, **2011**, 179, 1693-705 | 5.8 | 47 |
| 92 | Pulmonary artery denervation reduces pulmonary artery pressure and induces histological changes in an acute porcine model of pulmonary hypertension. *Circulation: Cardiovascular Interventions*, **2015**, 8, e002569 | 6 | 46 |
| 91 | Apolipoprotein D inhibits platelet-derived growth factor-BB-induced vascular smooth muscle cell proliferated by preventing translocation of phosphorylated extracellular signal regulated kinase 1/2 to the nucleus. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2003**, 23, 2172-7 | 9.4 | 46 |
| 90 | Characterization of Mutations and Levels of BMP9 and BMP10 in Pulmonary Arterial Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 201, 575-585 | 10.2 | 46 |
| 89 | Identification of Long Noncoding RNA H19 as a New Biomarker and Therapeutic Target in Right Ventricular Failure in Pulmonary Arterial Hypertension. *Circulation*, **2020**, 142, 1464-1484 | 16.7 | 46 |
| 88 | Hypoxia determines survival outcomes of bacterial infection through HIF-1alpha dependent re-programming of leukocyte metabolism. *Science Immunology*, **2017**, 2, | 28 | 45 |
| 87 | Pulmonary Artery Denervation Attenuates Pulmonary Arterial Remodeling in Dogs With Pulmonary Arterial Hypertension Induced by Dehydrogenized Monocrotaline. *JACC: Cardiovascular Interventions*, **2015**, 8, 2013-2023 | 5 | 42 |
| 86 | The impact of patient choice on survival in chronic thromboembolic pulmonary hypertension. *European Respiratory Journal*, **2018**, 52, | 13.6 | 41 |

| | | | |
|---|---|---|---|
| 85 | Blood flow suppresses vascular Notch signalling via dll4 and is required for angiogenesis in response to hypoxic signalling. *Cardiovascular Research*, **2013**, 100, 252-61 | 9.9 | 41 |
| 84 | Toll-like Receptor 3 Is a Therapeutic Target for Pulmonary Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 199, 199-210 | 10.2 | 39 |
| 83 | A toolbox for the longitudinal assessment of healthspan in aging mice. *Nature Protocols*, **2020**, 15, 540-574 | 13.8 | 38 |
| 82 | Identification of Cardiac Magnetic Resonance Imaging Thresholds for Risk Stratification in Pulmonary Arterial Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 201, 458-468 | 10.2 | 37 |
| 81 | Telomerecat: A ploidy-agnostic method for estimating telomere length from whole genome sequencing data. *Scientific Reports*, **2018**, 8, 1300 | 4.9 | 33 |
| 80 | Loss-of-Function ABCC8 Mutations in Pulmonary Arterial Hypertension. *Circulation Genomic and Precision Medicine*, **2018**, 11, e002087 | 5.2 | 33 |
| 79 | Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension. *BMC Pulmonary Medicine*, **2018**, 18, 41 | 3.5 | 31 |
| 78 | Apolipoprotein D and platelet-derived growth factor-BB synergism mediates vascular smooth muscle cell migration. *Circulation Research*, **2004**, 95, 179-86 | 15.7 | 29 |
| 77 | Bosutinib therapy resulting in severe deterioration of pre-existing pulmonary arterial hypertension. *European Respiratory Journal*, **2016**, 48, 1514-1516 | 13.6 | 29 |
| 76 | Comprehensive Cancer-Predisposition Gene Testing in an Adult Multiple Primary Tumor Series Shows a Broad Range of Deleterious Variants and Atypical Tumor Phenotypes. *American Journal of Human Genetics*, **2018**, 103, 3-18 | 11 | 27 |
| 75 | Deficiency of tumour necrosis factor-related apoptosis-inducing ligand exacerbates lung injury and fibrosis. *Thorax*, **2012**, 67, 796-803 | 7.3 | 25 |
| 74 | Specific Alleles of CLN7/MFSD8, a Protein That Localizes to Photoreceptor Synaptic Terminals, Cause a Spectrum of Nonsyndromic Retinal Dystrophy **2017**, 58, 2906-2914 | | 24 |
| 73 | The role of chemokines and chemokine receptors in pulmonary arterial hypertension. *British Journal of Pharmacology*, **2021**, 178, 72-89 | 8.6 | 23 |
| 72 | Loss of Endothelial Endoglin Promotes High-Output Heart Failure Through Peripheral Arteriovenous Shunting Driven by VEGF Signaling. *Circulation Research*, **2020**, 126, 243-257 | 15.7 | 21 |
| 71 | Serum osteoprotegerin is increased and predicts survival in idiopathic pulmonary arterial hypertension. *Pulmonary Circulation*, **2012**, 2, 21-7 | 2.7 | 20 |
| 70 | A machine learning cardiac magnetic resonance approach to extract disease features and automate pulmonary arterial hypertension diagnosis. *European Heart Journal Cardiovascular Imaging*, **2021**, 22, 236-245 | 4.1 | 20 |
| 69 | Elevated plasma CXCL12 is associated with a poorer prognosis in pulmonary arterial hypertension. *PLoS ONE*, **2015**, 10, e0123709 | 3.7 | 19 |
| 68 | The Hepcidin/Ferroportin axis modulates proliferation of pulmonary artery smooth muscle cells. *Scientific Reports*, **2018**, 8, 12972 | 4.9 | 19 |

| | | | |
|---|---|---|---|
| 67 | Differential IL-1 signaling induced by BMPR2 deficiency drives pulmonary vascular remodeling. *Pulmonary Circulation*, **2017**, 7, 768-776 | 2.7 | 18 |
| 66 | De Novo Truncating Mutations in WASF1 Cause Intellectual Disability with Seizures. *American Journal of Human Genetics*, **2018**, 103, 144-153 | 11 | 18 |
| 65 | Bi-allelic Loss-of-Function CACNA1B Mutations in Progressive Epilepsy-Dyskinesia. *American Journal of Human Genetics*, **2019**, 104, 948-956 | 11 | 17 |
| 64 | Traffic exposures, air pollution and outcomes in pulmonary arterial hypertension: a UK cohort study analysis. *European Respiratory Journal*, **2019**, 53, | 13.6 | 17 |
| 63 | Divergent Roles for TRAIL in Lung Diseases. *Frontiers in Medicine*, **2018**, 5, 212 | 4.9 | 16 |
| 62 | Heart rate reduction with ivabradine promotes shear stress-dependent anti-inflammatory mechanisms in arteries. *Thrombosis and Haemostasis*, **2016**, 116, 181-90 | 7 | 16 |
| 61 | Screening strategies for pulmonary arterial hypertension. *European Heart Journal Supplements*, **2019**, 21, K9-K20 | 1.5 | 16 |
| 60 | Biallelic Mutation of ARHGEF18, Involved in the Determination of Epithelial Apicobasal Polarity, Causes Adult-Onset Retinal Degeneration. *American Journal of Human Genetics*, **2017**, 100, 334-342 | 11 | 14 |
| 59 | Maintained right ventricular pressure overload induces ventricular-arterial decoupling in mice. *Experimental Physiology*, **2017**, 102, 180-189 | 2.4 | 14 |
| 58 | Whole-Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical Outcome. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 202, 586-594 | 10.2 | 14 |
| 57 | Zebrafish as a tractable model of human cardiovascular disease. *British Journal of Pharmacology*, **2021**, | 8.6 | 14 |
| 56 | Incremental shuttle walk test distance and autonomic dysfunction predict survival in pulmonary arterial hypertension. *Journal of Heart and Lung Transplantation*, **2017**, 36, 871-879 | 5.8 | 13 |
| 55 | Utilising artificial intelligence to determine patients at risk of a rare disease: idiopathic pulmonary arterial hypertension. *Pulmonary Circulation*, **2019**, 9, 2045894019890549 | 2.7 | 13 |
| 54 | Identifying early pulmonary arterial hypertension biomarkers in systemic sclerosis: machine learning on proteomics from the DETECT cohort. *European Respiratory Journal*, **2021**, 57, | 13.6 | 12 |
| 53 | A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension. *Nature Communications*, **2019**, 10, 5183 | 17.4 | 12 |
| 52 | High levels of healthcare utilization prior to diagnosis in idiopathic pulmonary arterial hypertension support the feasibility of an early diagnosis algorithm: the SPHInX project. *Pulmonary Circulation*, **2018**, 8, 2045894018798613 | 2.7 | 12 |
| 51 | A report on the use of animal models and phenotyping methods in pulmonary hypertension research. *Pulmonary Circulation*, **2014**, 4, 2-9 | 2.7 | 11 |
| 50 | Hypoxia down-regulates cyclic guanidine monophosphate-dependent protein kinase in fetal pulmonary vascular smooth muscle cell through generation of reactive oxygen species and promotes development of pulmonary hypertension. *Chest*, **2005**, 128, 577S-578S | 5.3 | 11 |

| | | | |
|---|---|---|---|
| 49 | Mts1/S100A4 stimulates human pulmonary artery smooth muscle cell migration through multiple signaling pathways. *Chest*, **2005**, 128, 577S | 5.3 | 11 |
| 48 | Rare variant analysis of 4241 pulmonary arterial hypertension cases from an international consortium implicates FBLN2, PDGFD, and rare de novo variants in PAH. *Genome Medicine*, **2021**, 13, 80 | 14.4 | 11 |
| 47 | MicroRNA in pulmonary vascular disease. *Progress in Molecular Biology and Translational Science*, **2014**, 124, 43-63 | 4 | 10 |
| 46 | Circulating Protein Biomarkers in Systemic Sclerosis Related Pulmonary Arterial Hypertension: A Review of Published Data. *Frontiers in Medicine*, **2018**, 5, 175 | 4.9 | 9 |
| 45 | Bayesian Inference Associates Rare Variants with Specific Phenotypes in Pulmonary Arterial Hypertension. *Circulation Genomic and Precision Medicine*, **2020**, | 5.2 | 9 |
| 44 | Altered Macrophage Polarization Induces Experimental Pulmonary Hypertension and Is Observed in Patients With Pulmonary Arterial Hypertension. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2021**, 41, 430-445 | 9.4 | 8 |
| 43 | Selective improvement of pulmonary arterial hypertension with a dual ET/ET receptors antagonist in the apolipoprotein E model of PAH and atherosclerosis. *Pulmonary Circulation*, **2018**, 8, 2045893217752328 | 2.7 | 8 |
| 42 | Influence of pre-analytical and analytical factors on osteoprotegerin measurements. *Clinical Biochemistry*, **2014**, 47, 1279-85 | 3.5 | 7 |
| 41 | From bones to blood pressure, developing novel biologic approaches targeting the osteoprotegein pathway for pulmonary vascular disease. *Pharmacology & Therapeutics*, **2017**, 169, 78-82 | 13.9 | 6 |
| 40 | No evidence for cardiac dysfunction in Kif6 mutant mice. *PLoS ONE*, **2013**, 8, e54636 | 3.7 | 6 |
| 39 | A diagnostic miRNA signature for pulmonary arterial hypertension using a consensus machine learning approach. *EBioMedicine*, **2021**, 69, 103444 | 8.8 | 5 |
| 38 | The incremental shuttle walk test predicts mortality in non-group 1 pulmonary hypertension: results from the ASPIRE Registry. *Pulmonary Circulation*, **2019**, 9, 2045894019848649 | 2.7 | 4 |
| 37 | The role of the osteoprotegerin/tumor necrosis factor related apoptosis-inducing ligand axis in the pathogenesis of pulmonary arterial hypertension. *Vascular Pharmacology*, **2014**, 63, 114-7 | 5.9 | 4 |
| 36 | Rare variant analysis of 4,241 pulmonary arterial hypertension cases from an international consortium implicate FBLN2, PDGFD and rare de novo variants in PAH | | 4 |
| 35 | Incremental Shuttle Walking Test Distance Is Reduced in Patients With Pulmonary Hypertension in World Health Organisation Functional Class I. *Frontiers in Medicine*, **2018**, 5, 172 | 4.9 | 3 |
| 34 | TRAIL Deficient Mice Are Protected from Sugen/Hypoxia Induced Pulmonary Arterial Hypertension. *Diseases (Basel, Switzerland)*, **2014**, 2, 260-273 | 4.4 | 3 |
| 33 | VP22-mediated intercellular transport correlates with enhanced biological activity of MybEngrailed but not (HSV-I) thymidine kinase fusion proteins in primary vascular cells following non-viral transfection. *Journal of Gene Medicine*, **2005**, 7, 375-85 | 3.5 | 3 |
| 32 | Bayesian inference associates rare KDR variants with specific phenotypes in pulmonary arterial hypertension | | 3 |

| | | | |
|---|---|---|---|
| 31 | Right Ventricular Adaptation Assessed Using Cardiac Magnetic Resonance Predicts Survival in Pulmonary Arterial Hypertension. *JACC: Cardiovascular Imaging*, **2021**, 14, 1271-1272 | 8.4 | 3 |
| 30 | T5 MicroRNA-140-5p Regulates Disease Phenotype in Experimental Pulmonary Arterial Hypertension via SMURF1. *Thorax*, **2015**, 70, A3.1-A3 | 7.3 | 2 |
| 29 | Repeatability and Sensitivity to change of right ventricular analysis methods using cardiac magnetic resonance imaging in PAH: results from the RESPIRE Study **2019**, | | 2 |
| 28 | Frataxin and endothelial cell senescence in pulmonary hypertension. *Journal of Clinical Investigation* , **2021**, 131, | 15.9 | 2 |
| 27 | Repeatability and sensitivity to change of non-invasive end points in PAH: the RESPIRE study. *Thorax*, **2021**, 76, 1032-1035 | 7.3 | 2 |
| 26 | The Latest in Animal Models of Pulmonary Hypertension and Right Ventricular Failure.. *Circulation Research*, **2022**, 130, 1466-1486 | 15.7 | 2 |
| 25 | Prognostic Significance of Reduced Blood Pressure Response to Exercise in Pediatric Pulmonary Arterial Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 196, 1478-1481 | 10.2 | 1 |
| 24 | T5 Opg Regulates Pulmonary Arterial Smooth Muscle Cell Proliferation And The Expression Of Pah-associated Genes Via Fas. *Thorax*, **2014**, 69, A2-A3 | 7.3 | 1 |
| 23 | S111 The role of TNF-related apoptosis inducing ligand (TRAIL) in pulmonary fibrosis. *Thorax*, **2011**, 66, A51-A52 | 7.3 | 1 |
| 22 | Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood. *Nature Communications*, **2021**, 12, 7104 | 17.4 | 1 |
| 21 | E microRNA-140-5p and SMURF1 Regulate Pulmonary Arterial Hypertension. *Heart*, **2016**, 102, A147-A147 | 5.1 | 1 |
| 20 | P245 Whole blood levels of microrna-34a predict survival and regulate genes associated with pulmonary arterial hypertension. *Thorax*, **2016**, 71, A220.2-A221 | 7.3 | 1 |
| 19 | Deprivation and prognosis in patients with pulmonary arterial hypertension: missing the effect of deprivation on a rare disease?. *European Respiratory Journal*, **2020**, 56, | 13.6 | 1 |
| 18 | Maximal Exercise Testing Using the Incremental Shuttle Walking Test Can Be Used to Risk-Stratify Patients with Pulmonary Arterial Hypertension. *Annals of the American Thoracic Society*, **2021**, 18, 34-43 | 4.7 | 1 |
| 17 | Imaging and Risk Stratification in Pulmonary Arterial Hypertension: Time to Include Right Ventricular Assessment.. *Frontiers in Cardiovascular Medicine*, **2022**, 9, 797561 | 5.4 | 1 |
| 16 | Training and clinical testing of artificial intelligence derived right atrial cardiovascular magnetic resonance measurements.. *Journal of Cardiovascular Magnetic Resonance*, **2022**, 24, 25 | 6.9 | 1 |
| 15 | S107 Genotype-phenotype associations in pulmonary arterial hypertension caused by BMPR2 and EIF2AK4 variants. *Thorax*, **2016**, 71, A63-A64 | 7.3 | |
| 14 | 183 Novel OPG Protein Interactions Regulate Survival, Proliferation And Pah-associated Gene Expression in Pulmonary Arterial Smooth Muscle Cells. *Heart*, **2014**, 100, A102.3-A103 | 5.1 | |

| | | |
|---|---|---|
| 13 | 156 Inducers of pulmonary arterial hypertension upregulate the expression of plasma membrane calcium atpase 1 in pulmonary artery smooth muscle cells. *Heart*, **2017**, 103, A113.1-A113 | 5.1 |
| 12 | S3 Reduced BMPR2 expression potentiates a pulmonary artery smooth muscle cell specific IL-1 response. *Thorax*, **2015**, 70, A5.3-A6 | 7.3 |
| 11 | P157 Hepatocyte growth factor concentration correlates with haemodynamic severity in connective tissue disease-associated pulmonary arterial hypertension. *Thorax*, **2013**, 68, A146.2-A147 | 7.3 |
| 10 | S151 TRAIL deficiency is protective in experimental pulmonary arterial hypertension. *Thorax*, **2010**, 65, A68-A68 | 7.3 |
| 9 | P34 Characterising T cell sub-populations in pulmonary hypertension. *Thorax*, **2010**, 65, A91-A91 | 7.3 |
| 8 | 14 The role of TILRR in vascular cell inflammation and development of atherosclerosis. *Heart*, **2011**, 97, e7-e7 | 5.1 |
| 7 | T6 TRAIL is a potential novel therapeutic target in pulmonary arterial hypertension. *Thorax*, **2011**, 66, A3-A3 | 7.3 |
| 6 | P5 Pulmonary hypertension in a mouse model with reduced macrophage number (MacLow). *Thorax*, **2011**, 66, A68-A69 | 7.3 |
| 5 | S69 Serum osteoprotegerin predicts mortality in a prospective study on incident cases of pulmonary arterial hypertension. *Thorax*, **2011**, 66, A34-A34 | 7.3 |
| 4 | 03 Tissue Trail Drives Pulmonary Vascular Remodeling and its Inhibition Reverses Experimental Pulmonary Arterial Hypertension. *Heart*, **2012**, 98, A1.3-A1 | 5.1 |
| 3 | S85 Reduction of CD68 macrophages causes gender specific spontaneous pulmonary arterial hypertension in mice. *Thorax*, **2016**, 71, A49.1-A49 | 7.3 |
| 2 | S87 Deficiency of toll-like receptor 3 (TLR3) exacerbates pulmonary hypertension in mice. *Thorax*, **2016**, 71, A50.1-A50 | 7.3 |
| 1 | S104 Hypoxia preconditions the innate immune response to acute bacterial pulmonary infections. *Thorax*, **2016**, 71, A61.2-A62 | 7.3 |